Recordati (RECI: MI) says it has acquired 100% of the share capital of fellow Italian drugmaker Italchimici SpA from current owners Progressio SGR, manager of the fund Progressio Investimenti II, IDeA Capital Funds SGR, manager of the fund Fondo IDeA Efficienza Energetica e Sviluppo Sostenibile, and from managers of the company itself.
The value of the transaction is around 130 million euros ($145 million) and will be funded from existing liquidity. The signing and closing of the transaction took place at the same time.
Italchimici, with over 40 years of history and revenues in 2015 of 46 million euros, is a consolidated firm in the Italian pharmaceutical market with well-known products. The company offers therapeutic solutions mainly in the gastroenterological and respiratory areas which consist of both pharmaceutical products and food supplements and medical devices to improve the health and well-being of patients. The main brands in its extensive product portfolio are Reuflor, Peridon and Lacdigest in the gastroenterological offering and Aircort among the respiratory products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze